Lentivirus-modified hematopoietic stem cell gene therapy for advanced symptomatic juvenile metachromatic leukodystrophy: a long-term follow-up pilot study

Abstract

Metachromatic leukodystrophy (MLD) is an inherited disease caused by a deficiency of the enzyme arylsulfatase A (ARSA). Lentivirus-modified autologous hematopoietic stem cell gene therapy (HSCGT) has recently been approved for clinical use in pre and early symptomatic children with MLD to increase ARSA activity. Unfortunately, this advanced therapy is not available for most patients with MLD who have progressed to more advanced symptomatic stages at diagnosis. Patients with late-onset juvenile MLD typically present with a slower neurological progression of symptoms and represent a significant burden to the economy and healthcare system, whereas those with early onset infantile MLD die within a few years of symptom onset. We conducted a pilot study to determine the safety and benefit of HSCGT in patients with postsymptomatic juvenile MLD and report preliminary results. The safety profile of HSCGT was favorable in this long-term follow-up over 9 years. The most common adverse events (AEs) within 2 months of HSCGT were related to busulfan conditioning, and all AEs resolved. No HSCGT-related AEs and no evidence of distorted hematopoietic differentiation during long-term follow-up for up to 9.6 years. Importantly, to date, patients have maintained remarkably improved ARSA activity with a stable disease state, including increased Functional Independence Measure (FIM) score and decreased magnetic resonance imaging (MRI) lesion score. This long-term follow-up pilot study suggests that HSCGT is safe and provides clinical benefit to patients with post-symptomatic juvenile MLD.

Keywords

HSCGT / advanced symptomatic / metachromatic leukodystrophy / juvenile / patients / safety / efficacy

References

[1] Assadi M, Wang DJ, Anderson K et al. Vitamin K antagonist warfarin for palliative treatment of metachromatic leukodystrophy, a compassionate study of four subjects. J Cent Nerv Syst Dis 2012;4:73–79.

[2] Beschle J, Döring M, Kehrer C et al. Early clinical course after hematopoietic stem cell transplantation in children with juvenile metachromatic leukodystrophy. Mol Cell Pediatr 2020;7:12.

[3] Biffi A, Capotondo A, Fasano S et al. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J Clin Invest 2006;116:3070–3082.

[4] Biffi A, Lucchini G, Rovelli A et al. Metachromatic leukodystrophy: an overview of current and prospective treatments. Bone Marrow Transplant 2008;42:S2–S6.

[5] Biffi A, Montini E, Lorioli L et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013;341:1233158.

[6] Boucher AA, Miller W, Shanley R et al. Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report. Orphanet J Rare Dis 2015;10:94.

[7] Dali CI, Groeschel S, Moldovan M et al. Intravenous arylsulfatase A in metachromatic leukodystrophy: a phase 1/2 study. Ann Clin Transl Neurol 2021;8:66–80.

[8] Capotondo A, Milazzo R, Garcia-Manteiga JM et al. Intracerebroventricular delivery of hematopoietic progenitors results in rapid and robust engraftment of microglia-like cells. Sci Adv 2017;3:e1701211.

[9] Eichler F, Grodd W, Grant E et al. Metachromatic leukodystrophy: a scoring system for brain MR imaging observations. AJNR Am J Neuroradiol 2009;30:1893–1897.

[10] Fiedler RC, Granger CV. The functional independence measure: a measurement of disability and medical rehabilitation. In: Chino N, Melvin JL (eds.), Functional Evaluation of Stroke Patients. Tokyo: Springer Japan, 1996, 75–92.

[11] Fumagalli F, Calbi V, Natali Sora MG et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access. Lancet 2022;399:372–383.

[12] Gieselmann V, Krägeloh-Mann I. Metachromatic leukodystrophy—an update. Neuropediatrics 2010;41:1–6.

[13] Groeschel S, Kühl JS, Bley AE et al. Long-term outcome of allogeneic hematopoietic stem cell transplantation in patients with juvenile metachromatic leukodystrophy compared with nontransplanted control patients. JAMA Neurol 2016;73:1133–1140.

[14] Harrington M, Whalley D, Twiss J et al. Insights into the natural history of metachromatic leukodystrophy from interviews with caregivers. Orphanet J Rare Dis 2019;14:89.

[15] Kehrer C, Elgün S, Raabe C et al. Association of age at onset and first symptoms with disease progression in patients with metachromatic leukodystrophy. Neurology 2021;96:e255–e266.

[16] Krägeloh-Mann I, Groeschel S, Kehrer C et al. Juvenile metachromatic leukodystrophy 10 years post transplant compared with a non-transplanted cohort. Bone Marrow Transplant 2013;48:369–375.

[17] Ma L, Chung WK. Quantitative analysis of copy number variants based on real-time LightCycler PCR. Curr Protoc Hum Genet 2014;80:7.21.21–27.21.28.

[18] Ottenbacher KJ, Taylor ET, Msall ME et al. The stability and equivalence reliability of the functional independence measure for children (WeeFIM). Dev Med Child Neurol 1996;38:907–916.

[19] Schmidt M, Schwarzwaelder K, Bartholomae C et al. High-resolution insertion-site analysis by linear amplificationmediated PCR (LAM-PCR). Nat Methods 2007;4:1051–1057.

[20] Schoenmakers DH, Beerepoot S, van den Berg S et al. Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for metachromatic leukodystrophy: the European metachromatic leukodystrophy initiative (MLDi). Orphanet J Rare Dis 2022;17:48.

[21] Sessa M, Lorioli L, Fumagalli F et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet 2016;388:476–487.

[22] Sevin C, Roujeau T, Cartier N et al. Intracerebral gene therapy in children with metachromatic leukodystrophy: results of a phase I/II trial. Paper presented at:14 Annual WORLD Symposium (WORLD Symposium 2018), Vol. 123. Elsevier, 2018, S129.

[23] Shaimardanova AA, Chulpanova DS, Solovyeva VV et al. Metachromatic leukodystrophy: diagnosis, modeling, and treatment approaches. Front Med (Lausanne) 2020;7:576221.

[24] Ulaşlı AM, Türkmen U, Toktaş H et al. The complementary role of the Kinect virtual reality game training in a patient with metachromatic leukodystrophy. PM R 2014;6:564–567.

RIGHTS & PERMISSIONS

2024 The Author(s) 2024. Published by Oxford University Press on behalf of Higher Education Press.